Galip Can Uyar, Medical Doctor at Etlik City Hospital, shared a post on X about a recent article by Pablo Jimenez et al. published in Journal for ImmunoTherapy of Cancer:
“Can second-event endpoints truly capture the long-term benefit of anti–PD-(L)1 therapy?
Our new systematic review and meta-analysis in the Journal for ImmunoTherapy of Cancer provides compelling evidence:
- Second-event endpoints (EFS2, PRFS2, PFS2) are strongly aligned with overall survival across anti–PD-(L)1 randomized trials.
- In both metastatic and curative-intent NSCLC, immunotherapy shows a consistent and clinically meaningful advantage (pooled HR ≈ 0.73).
- The correlation between second-event endpoints and OS is exceptionally strong (R² ≈ 0.74), reinforcing their surrogate validity for long-term outcomes.
These findings underscore a crucial insight for immuno-oncology:
Post-progression endpoints are not merely secondary—they may serve as powerful predictors of true survival benefit.”
Title: Second-event endpoints (EFS2, PRFS2 and PFS2) after anti-PD-(L)1-based RCTs: a systematic review and meta-analysis
Authors: Pablo Jimenez, Oriol Mirallas, Ana Martin Quesada, Antonio Rullan, Dario Trapani, Teresa Amaral, Enriqueta Felip, Josep Tabernero, Kevin J. Harrington
Read the Full Article on Journal for ImmunoTherapy of Cancer
More posts featuring Galip Can Uyar.